Staidson (300204.SZ): Summary Report of Phase IIb Clinical Study of STSP-0601 for Injection

Staidson (300204.SZ) announcement, the company has obtained the Phase IIb clinical study summary report on the injection STSP-0601, with the indication for use as on-demand treatment for bleeding in patients with hemophilia A or B with inhibitors. The title of this study is: A multicenter, open-label evaluation of the efficacy and safety of injection STSP-0601 in adult hemophilia patients with inhibitors Phase IIb clinical study. The overall evaluation of this study is: The benefits of STSP-0601 in on-demand treatment of bleeding in patients with hemophilia A or B with inhibitors outweigh the risks.